[ad_1]
Johnson & Johnson
on Wednesday issued new financial guidance after spinning out the consumer-health company
Kenvue
While its earnings and sales projections were lowered on an absolute basis, the company is maintaining its dividend and expects to increase its revenue at a faster pace.
[ad_2]
[ad_1]
Johnson & Johnson
$35 billion exchange offer for
Kenvue
that expired last Friday was substantially oversubscribed. The result is that participating J&J holders will be able to convert only a fraction of their shares for Kenvue stock.
[ad_2]
[ad_1]
Johnson and Johnson
$40 billion exchange offer for shares in
Kenvue
is likely to generate strong interest from the healthcare company’s shareholders, resulting in participants being able to swap only a portion of their J&J stock.
[ad_2]
[ad_1]
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/kenvue-jnj-stock-price-exchange-offer-e85c3c90
[ad_2]
[ad_1]
Kenvue Inc. shares
KVUE,
were cheered in their Wall Street debut Thursday, as the Johnson & Johnson
JNJ,
spinoff, with consumer brands including Tylenol, Band-Aid and Listerine, saw it’s stock open 16.0% above its initial public offering price. Kenvue raised $3.8 billion as it said late Wednesday that it sold 172.8 million shares in the IPO, up from previous expectations of 151.2 million shares, at $22 a share, which was at the higher end of the expected pricing range of between $20 and $23 a share. With 1.87 billion shares outstanding after the IPO, the pricing values the company at $41.08 billion. The stock’s first trade was at $25.53 at 12:47 p.m. Eastern, for 15.7 million shares. At the opening price, the company was valued at $47.67 billion. Shares of J&J, which owns 1.72 billion Kenvue shares, or 91.9% of the shares outstanding, slipped 0.5% in midday trading. Kenvue’s debut comes at a time when the IPO market had all but dried up, and investors haven’t been showing shares of recent IPOs much love. The Renaissance IPO exchange-traded fund
IPO,
has lost 7.7% over the past three months while the S&P 500
SPX,
has slipped 1.8%.
[ad_2]
[ad_1]
Intraday Data provided by FACTSET and subject to terms of use.
Historical and current end-of-day data provided by FACTSET.
All quotes are in local exchange time.
Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.
[ad_2]